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Abstract: 
Background:  
Clostridium difficile infection (CDI) causes a high burden of disease in high-
resource healthcare systems, with significant morbidity, mortality and financial 
implications. CDI is a healthcare-associated infection for which the primary 
risk factor is antibiotic usage and it is the leading cause of bacterial diarrhoea 
in HIV infected patients in USA. Little is known about the disease burden of 
CDI in sub-Saharan Africa, where HIV and healthcare associated infection 
have a higher prevalence and antibiotic usage is less restricted. 
 
Aim:  
To review published literature on CDI in sub-Saharan Africa, highlighting 
areas for future research.  
 
Methods: 
English language publications since 1995 were identified from online 
databases (PubMed, Medline, Google Scholar, SCOPUS) and personal 
collections of articles, using combinations of keywords to include C. difficile, 
Africa and HIV.. 
 
Results:  
Ten relevant studies were identified. There is considerable variation in 
methodology to assess for carriage of toxigenic C. difficile and its 
associations. Eight studies report carriage of toxigenic C. difficile. Three (of 
four) studies found an association with antibiotic usage. One (of four) studies 
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showed an association with HIV infection. One study showed no association 
with degree of immunosuppression in HIV. Two (of three) studies showed an 
association between carriage of toxigenic C. difficile and diarrhoeal illness. 
 
Conclusion:  
Whilst the carriage of toxigenic C. difficile is well described in sub-Saharan 
Africa, the impact of CDI in the Region remains poorly l understood and 
warrants high quality research.  
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Introduction: 
Clostridium difficile, an anaerobic Gram-positive spore-forming bacterium, 
was first described in neonatal gut, and was initially presumed to be a 
commensal organism in 1935.1 Later, it was recognised to cause 
pseudomembranous colitis via toxin production and it has since emerged as a 
major enteric pathogen.2, 3 Its clinical significance ranges from asymptomatic 
carriage to life threatening colitis, with significant associated morbidity and 
mortality. C. difficile colonises the large bowel following ingestion of spores, 
which are heat and acid resistant.4 The spores can be found in all healthcare 
settings and in the general environment. 5, 6 Gut damage in susceptible 
individuals results from production of two exotoxins, TcdA and TcdB, whose 
action is cytotoxic.7 The emergence of the 027/BI/NAP1 strain, with 
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dramatically increased cytotoxin production, is responsible for the observed 
increased prevalence and virulence of C. difficile in recent years.8-10 This 
strain emerged in North America and Western Europe and rapidly 
disseminated worldwide.11  
 
The primary risk factor for C difficile infection (CDI) is antibiotic usage. CDI is 
known to be the cause of up to 25% of antibiotic associated diarrhoea.12 CDI 
was originally described following clindamycin use but is now known to 
complicate the use of many broad spectrum antibiotics, particularly 
cephalosporins, co-amoxiclav and fluoroquinolones.3, 13 Following antibiotic 
usage, there is an imbalance in the normal gut flora and C. difficile overgrowth 
can lead to pseudomembranous colitis in susceptible individuals.14 Other 
described risk factors for CDI include hospital admission, exposure to an 
infected carrier, advanced age and immunosupression.15. The importance of 
proton pump inhibitors and of other interventions that reduce the gastric acid 
barrier in increasing susceptibility to CDI remains controversial. 16, 17 There is 
a described relationship between CDI and HIV in USA where it is known to be 
the leading cause of bacterial diarrhoea in HIV-infected populations, but it is 
not clear how much this reflects increased exposure to healthcare compared 
to HIV negative individuals.18, 19 Only two studies show a convincing 
associated between CDI and low CD4 count, and interpretation of these 
results is difficult given the high rates of C. difficile colonisation in HIV infected 
populations.19-22  
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While CDI has been extensively researched in well-resourced health systems, 
there are few published studies about CDI in sub-Saharan Africa. It is known 
that healthcare associated infections cause a greater disease burden in 
healthcare systems with fewer resources.23 Furthermore the main risk factor 
for CDI is antibiotic usage and in sub-Saharan Africa there is widespread 
availability of broad-spectrum antibiotics and fewer controls on their usage.24 
Finally, HIV is far more prevalent in sub-Saharan Africa than in USA or 
Europe. It is, therefore, possible that CDI plays an important role in diarrhoeal 
illness in sub-Saharan Africa, yet there are very few published data on the 
subject. Published infection rates vary greatly, with some authors describing 
0% prevalence in Kenya and Zambia, whilst the highest published rate is from 
Nigeria at 43%.25-27 The nature of the relationship between HIV and CDI in 
sub-Saharan Africa remains poorly understood.  
 
The aim of this review is to describe current published literature regarding CDI 
in adults in Sub-Saharan Africa and to highlight areas warranting further 
research. 
 
Clostridium difficile Infection in Sub-Saharan Africa:  
 
In order to identify studies assessing CDI in adults in sub-Saharan Africa we 
performed a literature search for “Clostridium difficile” AND “Africa” in PubMed 
and Scopus. All relevant papers in English from 1995 onwards were included 
in the review and their bibliographies were reviewed for relevant papers. 
Papers looking at adults and children were only included if it was possible to 
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distinguish between the two populations. In total ten relevant studies were 
found. Data were extracted from relevant papers using a standardised 
proforma. 
 
Results: 
 
Ten studies looked for toxigenic C. difficile carriage in sub-Saharan Africa. Of 
these, eight describe toxigenic C.difficile carriage. There is considerable 
variation in laboratory methodology used to identify C. difficile and in the 
populations studied. Furthermore there is wide variation in the methodology 
used to assess the association of CDI with recent antibiotic usage, with HIV, 
with presence of symptoms of diarrhoea, and with degree of 
immunosupression. Table 1 summarises current published studies of CDI in 
adult populations in different countries in Sub-Saharan Africa. 
 
Discussion: 
 
The majority of published studies, and all studies after the year 2000, describe 
carriage of toxigenic C. difficile in adult populations in sub-Saharan Africa. In 
three studies, which assessed recent antibiotic exposure, there was a 
significant association between antibiotic exposure and CDI, however no 
studies were designed to implicate individual antibiotics.29, 30, 34 These findings 
are consistent with the well-described risk factor of antibiotic usage in high 
resourced healthcare systems. In three of four studies, which assessed 
association with HIV status, no association was found. The only study 
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claiming an association between HIV status and CDI was from Nigeria and 
has significant methodological flaws, which require the conclusions to be 
viewed with caution.27 The lack of association between CDI and HIV status 
differs from observations in high-resource healthcare systems.18, 20, 21 The 
only study to assess the association between degree of immunosuppression 
in HIV and CDI is from Malawi.31 It showed no significant association between 
carriage of toxigenic C. difficile and severe immunosuppression (CD4 cell 
counts <50 x 106/L), although numbers in this group were small. This warrants 
assessment in a larger study population. The disease burden of CDI in sub-
Saharan Africa, particularly in areas of high HIV prevalence, has yet to be well 
characterized and warrants further research. 
 
A further area of uncertainty is the role that C. difficile plays in diarrhoeal 
illness, as opposed to asymptomatic infection and incidental detection, in 
populations studied in sub-Saharan Africa. Table 1 shows that a wide variety 
of laboratory methods have been used to detect C difficile in the different 
studies, with different sensitivities and specificities. Methods that use 
cytotoxicity or immunogenic assays to detect C. difficile toxin, reliably detect 
invasive CDI but sensitivity is variable and dependant on laboratory 
technique, while PCR based methods used alone probably result in 
overdiagnosis.35-38 Only one study used the two step diagnostic algorithms 
currently recommended in many countries, using assays for faecal C difficile 
glutamate dehydrogenase (GDH) as a screening test for presence of infection 
followed by confirmatory PCR for cytotoxin genes to diagnose invasive 
disease potential. 35 The majority of studies assessed C. difficile in patients 
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with diarrhoea and did not compare these to non-diarrhoeal controls. However 
the most robust study of CDI in sub-Saharan Africa showed a clear 
association between detection of toxigenic C. difficile and symptomatic 
diarrhoeal illness in South Africa.29 Another study of adults and children in 
Tanzania detected toxigenic C. difficile in 9 of 141 subjects with diarrhoea 
compared to none in the stools of 109 symptom free controls.34 Whilst 
asymptomatic carriage has been well documented and demonstrated to 
contribute to ongoing transmission of C. difficile in well-resourced healthcare 
systems, its significance in sub-Saharan Africa remains to be characterised 
altogether. 21, 22, 39, 40  
 
Only one study on CDI in South Africa described outcomes.33 There was an 
observed 66.7% mortality rate for patients with CDI and diarrhoea. However 
there was no statistical difference in mortality between patients with or without 
C. difficile, nor in length of stay and intensive care admission. Twelve percent 
of patients with CDI required colectomy, a finding that was significantly 
associated with the presence of toxigenic C. difficile. Whilst the presence of 
toxigenic C. difficile has been described in sub-Saharan Africa, its extent and 
clinical significance remain poorly understood. 
 
 
 
Conclusion: 
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There are relatively few studies on CDI in sub-Saharan Africa, but toxigenic C. 
difficile has been detected in the majority of studies designed to look for it in 
the region, where it is consistently associated with antibiotic exposure. Further 
high quality research is needed to define the epidemiology of CDI in sub-
Saharan Africa in order to clarify the extent of colonisation within community 
and hospitalised populations, the extent to which CDI is associated with HIV 
and CD4 count, and its role in contributing to morbidity and mortality.  
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Table 1.  Published studies on CDI in adults in sub-Saharan Africa. 1995 – 
present.  
Author Year Country Setting Controls Diagnostic 
test for CDI 
Study 
size 
(adults) 
CDI 
Prevalence 
(adults) 
Antibiotic 
association 
HIV 
association 
Mwachari25 1998 Kenya HIV positive 
adult 
inpatients 
with chronic 
diarrhoea 
n/a Cytotoxicity 
assay 
75 0% n/a n/a 
Germani28 1998 Central 
African 
Republic 
Adults 
presenting 
to hospital 
with 
diarrhoea  
HIV positive 
and negative 
non-diarrhoeal 
adult 
inpatients 
Cytotoxicity 
assay 
430 0.7% n/a n/a 
Zulu26 2000 Zambia HIV positive 
adult 
inpatients 
n/a ELISA for 
toxin A 
68 0% n/a n/a 
Samie29 2008 South Africa Adults and 
children in 
hospital and 
community 
with 
diarrhoea 
HIV positive 
and negative 
non-diarrhoeal 
adult in 
hospital and 
community  
PCR for 
cytotoxin 
genes 
135 17.8% Yes No 
Onwuema27 2011 Nigeria Adults and 
children in 
hospital and 
community 
with 
diarrhoea 
HIV negative 
(or unknown) 
adults in the 
community 
EIA for toxin 
A and B 
140 4.3% to 
43.5% 
n/a Yes 
Rajabally30 2013 South Africa Adult 
inpatients 
with 
diarrhoea  
n/a EIA for toxin 
A 
643 9.2% Yes No 
Beadsworth31 2014 Malawi Adult 
inpatients 
with 
diarrhoea 
HIV positive 
and negative 
non-diarrhoeal 
adult 
inpatients  
ELISA for 
toxin A and 
B 
206 13.6% n/a No 
Simango32 2014 Zimbabwe Adults and 
children in 
community 
with 
diarrhoea 
n/a Culture and 
EIA for toxin 
A and B 
159 6.9% n/a n/a 
Kullin33 2015 South Africa Adults in 
hospital and 
community 
with 
diarrhoea 
n/a PCR for 
cytotoxin 
genes 
156 16% n/a n/a 
Seugendo34 2015 Tanzania  Adults and 
children 
inpatients 
with 
diarrhoea 
Non-diarrhoeal 
adults in 
community 
Rapid test 
for GDH and 
PCR for 
cytotoxin 
genes 
33 9.1% Yes n/a 
 
Key:  CDI = Clostridium difficile infection, ELISA = Enzyme linked 
immunosorbent assay, PCR= polymerase chain reaction, EIA = Enzyme 
immunoassay, n/a = not assessed, GDH= glutamate dehydrogenase 
(Clostridium difficile specific). 
 
